Document Detail

Nerve-sparing radical retropubic prostatectomy in patients previously submitted to holmium laser enucleation of the prostate for bladder outlet obstruction due to benign prostatic enlargement.
MedLine Citation:
PMID:  17659829     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To evaluate the feasibility and safety of nerve-sparing radical retropubic prostatectomy (NSRRP) for localised prostate cancer after holmium laser enucleation of the prostate (HoLEP) for bladder outlet obstruction due to benign prostatic enlargement (BPE). METHODS: Fifteen consecutive patients with prostate cancer following HoLEP underwent NSRRP. They were matched with an equal number of patients who also underwent NSRRP following transurethral resection of the prostate (TURP group) or open prostatectomy (OP group). Patients were preoperatively assessed with validated questionnaires (International Prostate Symptom Score [IPSS] and International Index of Erectile Function-Erectile Function [IIEF-EF]). Intraoperative, perioperative, and follow-up functional data according to validated questionnaires (IPSS, IIEF-EF, International Consultation on Incontinence Questionnaire-Short Form [ICIQ-SF]) were evaluated with analysis of variance and chi2 tests. RESULTS: At diagnosis, the prostate-specific antigen (PSA) level, clinical stage, Gleason sum distributions, body mass index, ICIQ-SF, and IPSS were not significantly different among the groups. IIEF-EF scores was higher in the HoLEP group (p=0.02). Mean operative time was longer in the OP group (p=0.02), but no difference was found in mean blood loss (p=0.5). Final pathology showed no substantial differences among the groups, although a lower positive surgical margin rate was found in the HoLEP group (p=0.04). Mean follow-up was 23.8+/-10.5 mo. The groups showed no statistical differences in urinary continence rate (p=0.6), IPSS (p=0.3), or IIEF-EF (p=0.4). CONCLUSIONS: NSRRP is feasible in prostate cancer patients who previously underwent HoLEP for BPE and provides satisfactory functional outcomes.
Nazareno Suardi; Vincenzo Scattoni; Alberto Briganti; Andrea Salonia; Richard Naspro; Andrea Gallina; Andrea Cestari; Renzo Colombo; Pierre I Karakiewicz; Giorgio Guazzoni; Patrizio Rigatti; Francesco Montorsi
Related Documents :
16999629 - Erectile dysfunction after plasmakinetic vaporization of the prostate: incidence and ri...
17141839 - Quality of life after brachytherapy or radical prostatectomy for localized prostate can...
8252509 - Combination treatment in m1 prostate cancer.
16690359 - A phase i trial of intravenous cg7870, a replication-selective, prostate-specific antig...
10233489 - A prospective randomized controlled trial of hybrid laser treatment or transurethral re...
10374789 - Outcome analysis of minimally invasive treatments for benign prostatic hyperplasia.
24965759 - Determination of steroid injection sites using lidocaine test in adhesive capsulitis: a...
21463789 - Oncologic efficacy is not compromised, and may be improved with minimally invasive esop...
8419869 - Tranexamic acid as a mouthwash in anticoagulant-treated patients undergoing oral surger...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2007-07-23
Journal Detail:
Title:  European urology     Volume:  53     ISSN:  0302-2838     ISO Abbreviation:  Eur. Urol.     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-05-12     Completed Date:  2008-11-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7512719     Medline TA:  Eur Urol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  1180-5     Citation Subset:  IM    
Department of Urology, University Vita-Salute San Raffaele, Milan, Italy. <>
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Feasibility Studies
Laser Therapy*
Lasers, Solid-State*
Middle Aged
Prostatectomy / methods*
Prostatic Hyperplasia / complications*,  surgery*
Prostatic Neoplasms / surgery*
Urinary Bladder Neck Obstruction / etiology*,  surgery*
Comment In:
Eur Urol. 2008 Jun;53(6):1109-10   [PMID:  17681420 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessi...
Next Document:  Comment on "Removal of Supranol Yellow 4GL by adsorption onto Cr-intercalated montmorillonite".